D'Amico Gianpiero, Fabris Tommaso, Fraccaro Chiara, Tarantini Giuseppe
Dipartimento di Scienze Cardiache, Toraciche e Vascolari, Policlinico Universitario di Padova.
G Ital Cardiol (Rome). 2019 Mar;20(3 Suppl 1):35S-39S. doi: 10.1714/3121.31040.
Percutaneous mitral valve repair (MVR) using MitraClip system has been shown to be effective in patients with severe symptomatic mitral regurgitation deemed at high surgical risk. Atrial fibrillation is frequently observed in this setting, and the presence of a contraindication to oral anticoagulation is also very common in these patients. In this context, percutaneous left atrial appendage occlusion (LAAO) may be a valid alternative in reducing the thromboembolic risk. Since there is a large overlap between these two populations and the two procedures share some common steps, a combined approach of percutaneous MVR using the MitraClip system and LAAO may be considered a suitable strategy for patients with serious contraindications to both cardiac surgery and chronic antithrombotic therapy. Here we report the case of a patient affected by severe functional mitral regurgitation, secondary to post-infarction ventricular dilation, symptomatic for heart failure despite optimal medical therapy and cardiac resynchronization, and by atrial fibrillation with a contraindication for systemic anticoagulation due to high bleeding risk. Therefore, it was decided to perform a combined transcatheter procedure of MVR and LAAO.
使用MitraClip系统进行经皮二尖瓣修复术(MVR)已被证明对被认为手术风险高的严重症状性二尖瓣反流患者有效。在这种情况下,心房颤动经常出现,并且这些患者中口服抗凝治疗禁忌的情况也非常常见。在这种背景下,经皮左心耳封堵术(LAAO)可能是降低血栓栓塞风险的有效替代方法。由于这两类人群有很大重叠,且这两种手术有一些共同步骤,对于心脏手术和慢性抗栓治疗均有严重禁忌的患者,使用MitraClip系统进行经皮MVR和LAAO的联合方法可能是一种合适的策略。在此,我们报告一例患者,该患者因心肌梗死后心室扩张继发严重功能性二尖瓣反流,尽管接受了最佳药物治疗和心脏再同步治疗仍有心力衰竭症状,且患有心房颤动,因出血风险高而有全身抗凝治疗禁忌。因此,决定进行MVR和LAAO的联合经导管手术。